^
Association details:
| Biomarker: | CD34 positive + BMI1 overexpression + MAP2K1 elevation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | Mekinist (trametinib) (MEK inhibitor) + unesbulin (BMIi-1) (BMI1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
BMI1-Inhibitor PTC596 in Combination with MCL1 Inhibitor S63845 or MEK Inhibitor Trametinib in the Treatment of Acute Leukemia
Published date:
02/02/2021
Excerpt:
BMI1 and MN1 gene expression, and MCL1 and MEK1 protein levels were identified as biomarkers for response to PTC596 combination treatments...while PTC596 and trametinib may be more effective in CD34+ adverse risk AML with elevated BMI1 gene expression and MEK protein levels.
DOI:
10.3390/cancers13030581
